The FDA's compounding advisory committee reviews seven research peptides on July 23–24, 2026. Here's a claim-free look at what each molecule *is* — sequence, origin, and chemistry — plus the docket dates that matter.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will review seven peptides for possible inclusion on the Section 503A Bulks List. The public comment docket, FDA-2025-N-6895, closes to the committee on July 9; comments filed through July 22 are still considered by the agency. This is a regulatory-process update — not a statement about human use — and it's a good moment to understand what these molecules actually are.
The July 23 session covers four compounds, each listed in both free-base and acetate-salt forms. BPC-157 is a pentadecapeptide: a chain of fifteen amino acids corresponding to a fragment of a protein found in gastric juice. TB-500 is a synthetic peptide related to thymosin beta-4, a naturally occurring actin-binding protein studied in cell-motility and tissue biology. KPV is a tripeptide — lysine, proline, valine — that forms the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). MOTS-c is notable in its own right: it is one of the first peptides discovered to be encoded within the mitochondrial genome rather than the nucleus.
The July 24 session covers three more. Semax is a short peptide derived from a fragment of adrenocorticotropic hormone (ACTH), developed in Russia and often discussed in the neuropeptide literature. Epitalon (epithalon) is a synthetic tetrapeptide based on epithalamin, a pineal-gland extract studied in aging research. Emideltide is the name used on the docket for delta-sleep-inducing peptide (DSIP), a nonapeptide first isolated from cerebral venous blood in sleep research decades ago.
Why does the docket bother to name "free base" and "acetate" forms separately? Because salt form is part of a compound's chemical identity. It affects handling, solubility, and — importantly for a research context — how a reference standard is characterized and how a certificate of analysis reports purity and content. Two vials labeled with the same peptide name can differ in salt form, and rigorous documentation reflects that.
None of the above is a recommendation to use any of these substances. They remain research compounds, and the PCAC review is precisely about their regulatory status, not an endorsement of human use. What we can say with confidence is that clear chemistry and clear provenance are the right lens for anyone tracking this category: sequence, origin, salt form, and third-party analysis.
That's the standard we hold our own listings to. For every research compound we carry, we publish third-party certificates of analysis and lot/batch numbers so the identity and purity are documented rather than assumed. If you want to follow the PCAC outcome, mark July 23–24 — and read the molecules for what they are.
For Research Use Only. Not for human consumption.
> Compliance: strict · framing: chemistry/education/regulatory-news · flags: none — describes molecular identity and public docket facts; no dosing, no efficacy or disease language, CTA points to COAs/catalog, not a health promise.
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE. This content is educational and summarizes research literature; it is not medical advice or a product claim.
